BDMD
Baird Medical·NASDAQ
--
--(--)
--
--(--)
1.03 / 10
Underperform
Evaluation yields 1.0/10, reflecting concerning financial health. Key positives: ROA (%) and Annualized net profit margin on total assets (%), though challenges appear in Net cash flow from operating activities / Operating revenue (%) and Net profit / Total profit (%). This configuration appears guarded.
Analysis Checks(2/4)
ROA (%)
Value-14.66
Score2/3
Weight3.90%
1M Return-0.25%
Value-14.66
Score2/3
Weight3.90%
1M Return-0.25%
Annualized net profit margin on total assets (%)
Value-29.32
Score2/3
Weight3.90%
1M Return-0.25%
Value-29.32
Score2/3
Weight3.90%
1M Return-0.25%
Net cash flow from operating activities / Operating revenue (%)
Value-40.13
Score0/3
Weight61.46%
1M Return-6.20%
Value-40.13
Score0/3
Weight61.46%
1M Return-6.20%
Net profit / Total profit (%)
Value105.18
Score1/3
Weight30.74%
1M Return-2.49%
Value105.18
Score1/3
Weight30.74%
1M Return-2.49%
ROA (%)
Value-14.66
Score2/3
Weight3.90%
1M Return-0.25%
Value-14.66
Score2/3
Weight3.90%
1M Return-0.25%
Net cash flow from operating activities / Operating revenue (%)
Value-40.13
Score0/3
Weight61.46%
1M Return-6.20%
Value-40.13
Score0/3
Weight61.46%
1M Return-6.20%
Annualized net profit margin on total assets (%)
Value-29.32
Score2/3
Weight3.90%
1M Return-0.25%
Value-29.32
Score2/3
Weight3.90%
1M Return-0.25%
Net profit / Total profit (%)
Value105.18
Score1/3
Weight30.74%
1M Return-2.49%
Value105.18
Score1/3
Weight30.74%
1M Return-2.49%
Is BDMD undervalued or overvalued?
- BDMD scores 1.03/10 on fundamentals and holds a Premium valuation at present. Backed by its -29.96% ROE, -9.84% net margin, -7.71 P/E ratio, 0.69 P/B ratio, and -117.74% earnings growth, these metrics solidify its Underperform investment rating.
